26
Participants
Start Date
January 19, 2022
Primary Completion Date
March 5, 2024
Study Completion Date
October 31, 2025
TAK-771
Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Aichi Medical University Hospital, Nagakute
Chubu Rosai Hospital, Nagoya
Fujita Health University Hospital, Toyoake
Asahikawa Medical Center, Asahikawa
Kansai Rosai Hospital, Amagasaki
Hyogo College of Medicine Hospital, Nishinomiya
St.Marianna University School of Medicine Hospital, Kawasaki
Tohoku Medical and Pharmaceutical University Hospital, Sendai
Nara Medical University Hospital, Kashihara
Higashimatsuyama Municipal Hospital, Higashi-Matsuyama
Shiga University of Medical Science Hospital, Ōtsu
Tokushima National Hospital, Yoshinogawa
Juntendo University Hospital, Bunkyo-ku
National Center of Neurology and Psychiatry, Kodaira
Toho University Omori Medical Center, Ōta-ku
Tokyo Women's Medical University Hospital, Shinjuku-ku
Yamaguchi University Hospital, Ube
Chiba University Hospital, Chiba
Kyushu University Hospital, Fukuoka
Hiroshima University Hospital, Hiroshima
Kumamoto University Hospital, Kumamoto
Tokushima University Hospital, Tokushima
Toyama University Hospital, Toyama
Lead Sponsor
Takeda
INDUSTRY